• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Creative communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Plain Language Summary of Publication: What experts agree about using long-acting injectable antipsychotic medicine for people early in their experience of schizophrenia

Abstract

What is this summary about? Antipsychotics are a type of medicine used to treat the symptoms of schizophrenia. These medicines come in various forms, including long-acting injectables (LAIs), which are taken every few weeks or months. There may be differences amongst doctors in how they approach treatment of people who are in the early phase of schizophrenia and experiencing symptoms for the first time. For instance, there may be differences in how the doctors prescribe antipsychotics, or in how they judge that their patient has recovered enough to function in their daily lives (also known as functional recovery). This summary is based on two articles that reported results from a special process called the Delphi technique. This aimed to gain agreement from a group of experts on how LAI antipsychotics should be used for people living with early phase schizophrenia. Another aim was to gain agreement on what functional recovery looks like and how it can be assessed. Based on expert agreement obtained through the Delphi technique, people with early schizophrenia could benefit from LAI antipsychotics. It was also agreed that LAIs may help people living with early phase schizophrenia reach functional recovery. Functional recovery can be represented by key aspects including depression, aggressive behavior, and social interactions. In the future, it would be useful to develop a survey or questionnaire that could assess all these key aspects.

Authors A Fagiolini, Mt Yildirim, C Arango, P Gorwood, C U Correll, A Barlassina, E Arcà, J M Kane
Journal Therapeutic Advances in Psychopharmacology
Therapeutic Area Mental Health
Center of Excellence Patient-Centered outcomes
Year 2026
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Gender pay gap
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2026. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top